Process & Analytical Insights for GMP Manufacturing of mRNA-Lipid Nanoparticles

mRNA therapeutics are a rapidly expanding class of drugs but in the absence of standardized protocols, uncertainty exists surrounding the best approaches to process development and GMP manufacturing. In this Vaccine Insights webinar, learn how manufacturers can optimize their process to maximize their production workflow as well as the opportunities and challenges to the industrialized manufacture of mRNA-LNPs.
Panelists:
Emmanuelle Cameau, Gene Therapy Strategic Technology Partnership Leader EMEA, Pall Corporation
Peiqing Zhang, Gene Therapy Strategic Technology Partnership Leader APAC, Pall Corporation
Shell Ip, Client Learning and Scientific Content Manager, Precision NanoSystems
Linda Mathiasson, Strategic Customer Lead, Nucleic Acid Therapeutics, Cytiva
Katarina Stenklo, Enterprise Commercial Activation & End-to-End Solutions Leader, Cytiva